Gedeon Richter (RICHTER) Investor presentation summary

Company overview and strategic vision

• Over 125 years of history, with ~11,500 employees and 8 manufacturing sites globally.

• Four main business units: Women's Healthcare (WHC), Neuropsychiatry/CNS, Biotechnology (BIO), and General Medicines (GM).

• Vision for 2035 focuses on global recognition, innovation, affordability, and doubling non-royalty business size.

• Emphasis on improving quality of life, especially for women and mental health patients.

• Commitment to diversity, inclusion, and scalable, cost-efficient solutions.

Business segments and growth drivers

• WHC aims to double revenue by 2035, expand in the US and Western Europe, and lead in R&D and market innovation.

• CNS segment driven by Cariprazine (Vraylar®), a top-selling US drug, with global expansion and strong R&D partnerships.

• Biotech targets double-digit growth, break-even by 2027, and launches of biosimilars in immunology and musculoskeletal areas.

• GenMed focuses on generics excellence, portfolio freshness, and expansion in Western Europe.

• Multiple waves of new product launches and portfolio expansions planned through 2035.

Financial performance and outlook

• 2025 sales revenue reached EUR 2.3bn, with WHC contributing EUR 826mn.

• Clean EBIT margin improved to 34% in 2025, with steady-state margin expected to exceed 20% by 2030-31.

• H1 2026 CER revenue growth was 8.7%, with Clean EBIT up 21% YoY; strong cash flow and upgraded EBIT guidance.

• Ex-CNS revenues projected to more than double by 2035, driven by organic growth.

• Capital allocation prioritizes R&D (30-35% of pre-R&D cash), with sustainable dividends and flexibility for M&A.